Comparative Pharmacology
Head-to-head clinical analysis: PRESAMINE versus PROTRIPTYLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRESAMINE versus PROTRIPTYLINE HYDROCHLORIDE.
PRESAMINE vs PROTRIPTYLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Predominantly inhibits serotonin reuptake in the presynaptic neuron, increasing serotonin availability in the synaptic cleft. Also inhibits norepinephrine reuptake to a lesser extent.
Tricyclic antidepressant; inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. May also downregulate beta-adrenergic and serotonin receptors.
100-300 mg/day orally in divided doses, typically starting at 75 mg/day and titrating upward. Maximum dose 300 mg/day.
15 mg orally 3 to 4 times daily, not to exceed 60 mg per day.
None Documented
None Documented
21 hours (range 16-28 h) for imipramine; active metabolite desipramine ~24 h; clinically, steady-state reached in 5-7 days.
Terminal elimination half-life: 54-92 hours (mean ~74 hours); due to long half-life, steady-state is reached in 11-18 days.
Primarily renal (70% as metabolites, <5% unchanged); biliary/fecal (30%).
Primarily renal (50-70% as metabolites, <5% unchanged); biliary/fecal elimination accounts for ~10-20%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant